arrow
E

Emília Inoue Sato

universidade federal de são paulo (unifesp)
H指数:41
被引数:5,160

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort

比较COVID-19疫苗ChadOx-1、CoronaVac和BNT162b2在系统性红斑狼疮(SLE)患者中的免疫原性和安全性:一项前瞻性队列研究

2025-11-220
PRE
Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis

系统性血管炎患者对SARS-Cov-2疫苗接种的免疫原性和安全性

2025-11-180
OAAI
Primary and Booster COVID-19 Vaccination in Patients with Sjögren’s Disease: Data from the Longitudinal SAFER Cohort Study

原发性及加强剂COVID-19疫苗接种在舍格伦综合征患者中的效果:纵向SAFER队列研究数据

2025-11-150
OAAI
Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study

系统性红斑狼疮患者中SARS-CoV-2疫苗接种对COVID-19感染活动性和严重程度的影响:一项多中心队列研究

2025-10-210
OAAI
Validation cohort of a tool to predict proliferative histological class in lupus nephritis based on clinical and laboratory data: LUCAS Study (Lupus Nephritis Class Assessment System)

基于临床和实验室数据预测狼疮肾炎增生性病理分级的工具验证队列:LUCAS研究(狼疮肾炎分级评估系统)

2025-04-280
OA
Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study

系统性红斑狼疮患者SARS-CoV-2疫苗接种计划包括加强剂量的免疫原性: 来自前瞻性多中心研究的数据

2025-01-270
OAAI
Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort
2024-12-030
OAAI
Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study
2024-09-091
OAAI
IMMUNOGENICITY AND SAFETY OF COVID19 VACCINES IN PATIENTS WITH JUVENILE AUTOIMMUNE DISEASES: DATA FROM SAFER STUDY

COVID-19疫苗在青少年自身免疫性疾病患者中的免疫原性和安全性:SAFER研究数据

2024-06-010
PRE
BIVALENT MRNA COVID-19 VACCINE BOOSTER DOES NOT INCREASE THE RISK OF FLARE IN RHEUMATOID ARTHRITIS PATIENTS UNDER REAL LIFE SETTING - DATA FROM SAFER STUDY

双价mRNA COVID-19疫苗加强针在真实世界环境中不会增加类风湿关节炎患者的疾病复发风险——SAFER研究数据

2024-06-010
PRE
FACTORS ASSOCIATED WITH VACCINE RESPONSE AFTER COVID VACCINE BOOSTER IN PATIENTS WITH AUTOIMMUNE DISEASES: DATA FROM MULTICENTRIC PROSPECTIVE PHASE IV SAFER STUDY

与自身免疫性疾病患者COVID疫苗加强针后疫苗应答相关的因素:来自多中心前瞻性IV期SAFER研究的数据

2024-06-010
PRE
THE IMPACT OF ACTIVE LUPUS NEPHRITIS ON WORK PRODUCTIVITY IN PATIENTS FROM A LATIN AMERICAN LUPUS COHORT

活动性狼疮肾炎对拉丁美洲狼疮队列患者工作生产力的影响

2024-06-010
PRE
PREDICTORS OF HOSPITALIZATION DUETO BREAKTHROUGH COVID-19 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED RHEUMATIC DISEASES: DATA FROM SAFER STUDY

免疫介导性风湿病患者的突破性COVID-19感染住院预测因素:SAFER研究数据

2024-06-010
PRE
Role of plasma exchange in ANCA-associated vasculitis Reply
2023-10-010
PRE
Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis
2023-08-013
PRE
Pan American League of Associations for Rheumatology guidelines for the treatment of giant cell arteritis
2022-12-016
PRE
Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort
2019-03-0127
PREAI